Non-malignant Haematology

Clinical trials for patients with non-cancerous blood disorders.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email Clinical Trials Enquiries
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A phase 3, randomized, parallel-group, multicenter, open-label, pharmacokinetic noninferiority study of Ravulizumab administrated subcutaneously versus intravenously in adult patients with paroxysmal nocturnal hemoglobinuria currently treated with Eculizumab

Trial ID

NCT03056040

Cancer type

Paroxysmal nocturnal hemoglobinuria (or PNH, a condition that destroys red blood cells)

Status

On hold

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type

Brief summary

A clinical trial to test if the treatment ravulizumab is safe and better given subcutaneous (under the skin) or by intravenous (IV) infusion (given in liquid form, by injection into your vein) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

PNH is a disease of the blood where red blood cells are destroyed by a part of your immune system called the complement system. The treatment ravulizumab works by blocking complement activity.

Patients will be randomly selected to receive ravulizumab by either intravenous (IV) infusion or subcutaneous.

Who can participate

Patients who:

  • Are currently being treated with eculizumab (Soliris®) for at least 6 months prior to participation in the clinical trial

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.

Avatrombopag plus up Front ImmunosuppReSsive untreated severe aplastic Therapy in naïve severe aplastic anaemia

Trial ID

ACTRN12619001042134

Cancer type

Aplastic anaemia

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type

Brief summary

The clinical trial will test if the treatment Avatrombopag in addition to standard immunosuppressive therapy (IST) is safe and will increase the rate of production of red blood cells, white blood cells and platelets in patients with aplastic anaemia. Avatrombopag is given in liquid form by injection into the vein.

Aplastic anaemia is a rare but serious disease, where the body stops producing enough new blood cells (red blood cells, white blood cells, and platelets). Avatrombopag works by helping the body to make more platelets, which help control clotting and prevent bleeding. It is hoped the combination of Avatrombopag given with IST will improve treatment outcomes.

The standard treatment for aplastic anaemia is IST and bone marrow transplantation. Treatment depends on the severity of the disease, patient age, and the availability of a suitable bone marrow donor.

Who can participate

Patients who:

  • Have not been treated yet for aplastic anaemia

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Australia New Zealand Clinical Trial Registry.